| Identification | Back Directory | [Name]
CA1P | [CAS]
288847-34-7 | [Synonyms]
CA1P
OXi-4503 sodium
Tetrasodium A1 Diphosphate
COMBRETASTATIN A-1 PHOSPHATE
TetrasodiuM coMbretastatin A1 diphosphate
Oxi 4503 Combretastatin A-1 phosphate , CA1P
CoMbretastatin A1 diphosphate tetrasodiuM salt
tetrasodium,[3-methoxy-2-phosphonooxy-6-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] dihydrogen phosphate
3-Methoxy-6-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]-1,2-benzenediol bis(dihydrogen phosphate) tetrasodium salt | [Molecular Formula]
C18H23NaO12P2 | [MDL Number]
MFCD07368392 | [MOL File]
288847-34-7.mol | [Molecular Weight]
516.31 |
| Hazard Information | Back Directory | [Description]
OXi-4503 is the diphosphate prodrug of the stilbenoid combretastatin A1, originally isolated from the plant Combretum caffrum, with vascular-disrupting and antineoplastic activities. Upon administration, combretastatin A1 diphosphate (CA1P) is dephosphorylated to the active metabolite combretastatin A1 (CA1), which promotes rapid microtubule depolymerization; endothelial cell mitotic arrest and apoptosis, destruction of the tumor vasculature, disruption of tumor blood flow and tumor cell necrosis may ensue. |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|